Sumera H. Rizvi, M.B.B.S.

  1. Gastroenterologist
  2. Gastroenterologist (Transplant Hepatologist)
  3. Internist

Publications

  1. Rizvi S, Gores GJ. The Two Faces of Relaxin in Cancer: Antitumor or Protumor? Hepatology. 2019 Oct 20 [Epub ahead of print]
    View PubMed
  2. Loeuillard L, Conboy C, Gores GJ, Rizvi S. Immunobiology of Cholangiocarcinoma JHEP Reports. 2019; 1(4):297-311.
  3. Loeuillard E, Fischbach SR, Gores GJ, Rizvi S. Animal models of cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis. 2019 May 1; 1865 (5):982-992 Epub 2018 Apr 05
    View PubMed
  4. Rizvi S, Gores GJ. Fibroblast Growth Factor Receptor Inhibition for Cholangiocarcinoma: Looking Through a Door Half-Opened. Hepatology 2018 Dec; 68 (6):2428-2430 Epub 2018 Nov 07
    View PubMed
  5. Kabashima A, Hirsova P, Bronk SF, Hernandez MC, Truty MJ, Rizvi S, Kaufmann SH, Gores GJ. Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma. J Hepatol. 2018 Jun; 68 (6):1228-1238 Epub 2018 Mar 09
    View PubMed
  6. Rizvi S, Eaton J, Yang JD, Chandrasekhara V, Gores GJ. Emerging Technologies for the Diagnosis of Perihilar Cholangiocarcinoma. Semin Liver Dis. 2018 May; 38 (2):160-169 Epub 2018 June 05
    View PubMed
  7. Mertens JC, Rizvi S, Gores GJ. Targeting cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis. 2018 Apr; 1864 (4 Pt B):1454-1460 Epub 2017 Aug 24
    View PubMed
  8. Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018 Feb; 15 (2):95-111 Epub 2017 Oct 10
    View PubMed
  9. Rizvi S, Fischbach SR, Bronk SF, Hirsova P, Krishnan A, Dhanasekaran R, Smadbeck JB, Smoot RL, Vasmatzis G, Gores GJ. YAP-associated chromosomal instability and cholangiocarcinoma in mice. Oncotarget. 2018 Jan 19; 9 (5):5892-5905 Epub 2017 Dec 22
    View PubMed
  10. Anderson B, Rizvi S, Lin G, Nehra V. A case of heart failure and diarrhoea. Gut. 2017 Oct; 66 (10):1778 Epub 2016 Nov 09
    View PubMed
  11. Rizvi S, Gores GJ. Emerging molecular therapeutic targets for cholangiocarcinoma. J Hepatol. 2017 Sep; 67 (3):632-644 Epub 2017 Apr 05
    View PubMed
  12. Rizvi S, Yang JD, Gores GJ. Anti-GP2 IgA: a biomarker for disease severity and/or cholangiocarcinoma in primary sclerosing cholangitis? Gut 2017 Jan; 66 (1):4-5 Epub 2016 Sept 01
    View PubMed
  13. Rizvi S, Borad MJ. The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine? J Gastrointest Oncol. 2016 Oct; 7 (5):789-796
    View PubMed
  14. Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao FY, Vibert E, Cherqui D, Grant DR, Hernandez-Alejandro R, Dale CH, Cucchetti A, Pinna A, Hwang S, Lee SG, Agopian VG, Busuttil RW, Rizvi S, Heimbach JK, Montenovo M, Reyes J, Cesaretti M, Soubrane O, Reichman T, Seal J, Kim PT, Klintmalm G, Sposito C, Mazzaferro V, Dutkowski P, Clavien PA, Toso C, Majno P, Kneteman N, Saunders C, Bruix J, iCCA International Consortium. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology. 2016 Oct; 64 (4):1178-88 Epub 2016 Aug 24
    View PubMed
  15. Rizvi S, Yamada D, Hirsova P, Bronk SF, Werneburg NW, Krishnan A, Salim W, Zhang L, Trushina E, Truty MJ, Gores GJ. A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma. J Biol Chem. 2016 Apr 8; 291 (15):8031-47 Epub 2016 Jan 29
    View PubMed
  16. Rizvi S, Gores GJ. Liver capsule: Cholangiocarcinoma (CCA). Hepatology. 2016 Apr; 63 (4):1356 Epub 2016 Feb 01
    View PubMed
  17. Rizvi S, Yamada D, Hirsova P, Bronk S, Werneburg NW, Zhang L, Trushina E, Gores GJ. Mo1469 Fibroblast Growth Factor Receptor (FGFR) Signaling Activation Culminates in a Mcl-1 Regulated Tumor Survival Pathway in CC Gastroenterology. 2016; 150(4):S1124.
  18. Rizvi S, Eaton JE, Gores GJ. Primary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management. Clin Gastroenterol Hepatol. 2015 Nov; 13 (12):2152-65 Epub 2015 June 05
    View PubMed
  19. Yamada D, Rizvi S, Razumilava N, Bronk SF, Davila JI, Champion MD, Borad MJ, Bezerra JA, Chen X, Gores GJ. IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism. Hepatology. 2015 May; 61 (5):1627-42 Epub 2015 Mar 20
    View PubMed
  20. Rizvi S, Gores GJ. Molecular Profiling and Research of Therapeutic Targets. Dig Dis. 2015; 33 (4):586-9 Epub 2015 July 06
    View PubMed
  21. Rizvi S, Borad MJ, Patel T, Gores GJ. Cholangiocarcinoma: molecular pathways and therapeutic opportunities. Semin Liver Dis. 2014 Nov; 34 (4):456-64 Epub 2014 Nov 04
    View PubMed
  22. Rizvi S, Mertens JC, Bronk SF, Hirsova P, Dai H, Roberts LR, Kaufmann SH, Gores GJ. Platelet-derived growth factor primes cancer-associated fibroblasts for apoptosis. J Biol Chem. 2014 Aug 15; 289 (33):22835-49 Epub 2014 June 27
    View PubMed
  23. Hartman DJ, Krasinskas AM, Uttam S, Staton K, Bista R, Rizvi S, Slivka A, Brand R, Liu Y. Assessment of nuclear nanomorphology marker to improve the detection of malignancy from bile duct biopsy specimens. Am J Clin Pathol. 2014 Jun; 141 (6):884-91
    View PubMed
  24. Rizvi S, Gores GJ. Current diagnostic and management options in perihilar cholangiocarcinoma. Digestion. 2014; 89 (3):216-24 Epub 2014 May 22
    View PubMed
  25. Rizvi S, Gores GJ. Molecular pathogenesis of cholangiocarcinoma. Dig Dis. 2014; 32 (5):564-9 Epub 2014 July 14
    View PubMed
  26. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013 Dec; 145 (6):1215-29 Epub 2013 Oct 15
    View PubMed
  27. Fingas CD, Mertens JC, Razumilava N, Sydor S, Bronk SF, Christensen JD, Rizvi SH, Canbay A, Treckmann JW, Paul A, Sirica AE, Gores GJ. Polo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma. Hepatology. 2013 Oct; 58(4):1362-74. Epub 2013 Aug 06.
    View PubMed
  28. Fasanella KE, Bista RK, Staton K, Rizvi S, Uttam S, Zhao C, Sepulveda A, Brand RE, McGrath K, Liu Y. Nuclear Nano-architecture Markers of Gastric Cardia and Upper Squamous Esophagus Detect Esophageal Cancer "Field Effect". J Cancer. 2013; 4: (8)626-34.
    View PubMed
  29. Lomberk G, Mathison AJ, Grzenda A, Seo S, DeMars CJ, Rizvi S, Bonilla-Velez J, Calvo E, Fernandez-Zapico ME, Iovanna J, Buttar NS, Urrutia R. Sequence-specific recruitment of heterochromatin protein 1 via interaction with Kruppel-like factor 11, a human transcription factor involved in tumor suppression and metabolic diseases. J Biol Chem. 2012 Apr 13; 287 (16):13026-39 Epub 2012 Feb 08
    View PubMed
  30. Rizvi S, Schoen RE. Supplementation with oral vs. intravenous iron for anemia with IBD or gastrointestinal bleeding: is oral iron getting a bad rap? Am J Gastroenterol. 2011 Nov; 106: (11)1872-9.
    View PubMed
  31. Rizvi S, Demars CJ, Comba A, Gainullin VG, Rizvi Z, Almada LL, Wang K, Lomberk G, Fernandez-Zapico ME, Buttar NS. Combinatorial chemoprevention reveals a novel smoothened-independent role of GLI1 in esophageal carcinogenesis. Cancer Res. 2010 Sep 1; 70 (17):6787-96 Epub 2010 July 20
    View PubMed
  32. Buttar NS, DeMars CJ, Lomberk G, Rizvi S, Bonilla-Velez J, Achra S, Rashtak S, Wang KK, Fernandez-Zapico ME, Urrutia R. Distinct role of Kruppel-like factor 11 in the regulation of prostaglandin E2 biosynthesis. J Biol Chem. 2010 Apr 9; 285 (15):11433-44 Epub 2010 Feb 12
    View PubMed
PST-20258407